Medical device provider Teleflex has secured US Food and Drug Administration (FDA) 510(k) clearance to market its Arrow Midline with Chlorag+ard Technology.
The Arrow Midline is composed of medically validated flexible polyurethane and features safety hypo needles.
Chlorag+ard Technology is a chlorhexidine-based protective treatment from the ARROW brand. Its application involves the usage of a proprietary process whereby chlorhexidine is chemically fused to the catheter surface providing a controlled release.
The internal and external catheter surfaces are treated with chlorhexidine protection with Chlorag+ard Technology offering an initial burst of chlorhexidine with a sustained release resulting in antithrombogenic and antimicrobial protection.
Arrow Midline with Chlorag+ard Technology has been designed to reduce common midline catheter complications such as catheter intraluminal occlusion, thrombus accumulation and microbial colonisation on the catheter surface for a minimum of 30 days.
Additionally, the new midline can also be used with a high-pressure injection for diagnostic studies.
The Arrow Midline with Chlorag+ard Technology will allow the caregivers to effectively and economically secure the catheter from costly complications.
Teleflex vascular access division president and general manager Jay White said: “Clinicians are faced with a multitude of vascular access challenges.
"Development of new technology to ensure the patient receives the safest, most effective IV therapy possible should drive all medical device manufacturers.
“We at Teleflex continue to promote the message of ‘the right line for the right patient at the right time’ and through this belief we continue to develop products that help clinicians to champion better care.”